Novo Nordisk’s Wegovy Pill Hits 3M Prescriptions and Expands AI Drug Development
NVO•Novo Nordisk’s Wegovy pill reached over 3 million U.S. prescriptions within five months of launch, with 80% of new users naive to GLP-1 therapy, outpacing rival oral treatments. In April the company struck an OpenAI partnership to integrate AI across clinical data processes and accelerate weight-loss drug development.
1. Wegovy Pill Reaches 3M U.S. Prescriptions
Novo Nordisk’s oral GLP-1 treatment Wegovy has achieved over 3 million U.S. prescriptions within five months of launch, gaining 1 million scripts in the first 10–12 weeks and 2 million in the following 10 weeks, demonstrating rapid patient uptake.
2. Market Expansion and Competitive Position
More than 80% of new Wegovy prescriptions were written for patients with no prior GLP-1 therapy, indicating strong appeal among injection-averse users and positioning Novo Nordisk to narrow the gap with oral competitors introduced by Eli Lilly in April.
3. AI Partnership to Accelerate Weight-Loss Pipeline
In April, Novo Nordisk signed a deal with OpenAI to embed AI across its clinical data workflows, aiming to automate system setup, data processing, and regulator submissions to speed up weight-loss drug discovery and commercialization.
4. CEO Highlights Diversified Cardiometabolic Pipeline
At the American Diabetes Association’s 2026 Scientific Sessions, CEO Mike Doustdar described the company as a cardiometabolic powerhouse, emphasizing a strategy to diversify its pipeline and expand into new therapeutic areas.
